Evidence map›Paper›PMID 40195290›Full record

ReviewClinical and translational medicine2025

The role of cancer-associated fibroblasts in the tumour microenvironment of urinary system.

Ri Hong, Puguang Yu, Xiaoli Zhang, Peng Su, Hongyuan Liang, Dan Dong, Xuesong Wang, Kefeng Wang

Abstract readReview
In one paragraph

Review in Clinical and translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ri Hong *Department of Urology, Shengjing Hospital of China Medical University, Shenyang, China.
Puguang Yu *Department of Urology, Shengjing Hospital of China Medical University, Shenyang, China.
Xiaoli Zhang *Department of Critical Care Medicine, Shengjing Hospital of China Medical University, Shenyang, China.
Peng SuMedical Research Center, Shengjing Hospital of China Medical University, Shenyang, China.
Hongyuan LiangDepartment of Radiology, Shengjing Hospital of China Medical University, Shenyang, China.
Dan DongCollege of Basic Medical Science, China Medical University, Shenyang, China.
Xuesong WangDepartment of Urology, People's Hospital of China Medical University, Shenyang, China.
Kefeng WangDepartment of Urology, Shengjing Hospital of China Medical University, Shenyang, China.ORCID 0000-0003-0014-9182

Funding

National Natural Science Foundation of China
6 · The paper itself

Abstract

Urological tumours are a type of neoplasms that significantly jeopardise human life and wellbeing. Cancer-associated fibroblasts (CAFs), serving as the primary component of the stromal cellular milieu, form a diverse cellular cohort that exerts substantial influence on tumourigenesis and tumour progression. In this review, we summarised the literatures regarding the functions of CAFs in the urinary tumour microenvironment (TME). We primarily examined the multifaceted activities of CAFs in the TME of urological system tumours, including inhibiting tumour immunity, remodelling the extracellular matrix, promoting tumour growth, metastasis, drug resistance and their clinical applications. We also discussed potential future directions for leveraging artificial intelligence in CAFs research. KEY POINTS: The interaction of CAFs with various cell secretory factors in the TME of urological tumors. The application of CAFs in diagnosis, treatment and prognosis of urological tumors.

Indexed as

Cancer-Associated FibroblastsTumor MicroenvironmentUrologic NeoplasmsHumanscancer‐associated fibroblastsexosomesextracellular matriximmune systemtumour microenvironmenturological tumours

Identifiers

PMID40195290
PMCPMC11975626

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.